Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT07545603 by Evopoint Biosciences Inc., with 65 participants planned, started 2026-02-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: XNW5004 tablets. Conditions listed: Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A. No results are recorded here; the registry entry is the source.